EDRONAX

This brand name is authorized in Austria, Australia, Estonia, Croatia, Ireland, Israel, New Zealand, Poland, Turkey, United Kingdom, South Africa

Active ingredients

The drug EDRONAX contains one active pharmaceutical ingredient (API):

1 Reboxetine UNII L94J81YNNY - REBOXETINE MESYLATE

Reboxetine is a highly selective and potent inhibitor of noradrenaline reuptake. Noradrenaline reuptake inhibition and the consequent increase of noradrenaline availability in the synaptic cleft and modification of noradrenergic transmission, reportedly is among the most relevant mechanisms of action of known antidepressant drugs. Read about Reboxetine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EDRONAX Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06AX18	Reboxetine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8583R
Country: EE	Ravimiamet	Identifier(s): 1070930, 1640786, 1888500
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 142158, 161701, 22018, 373799
Country: IE	Health Products Regulatory Authority	Identifier(s): 22861
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4070
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 8169
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100098326
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308011008
Country: ZA	Health Products Regulatory Authority	Identifier(s): 33/1.2/0246